Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
Limited information is currently available on GEN-009, a putative cancer vaccine (Aug 2018).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GEN-009||GEN-009 is a personalized cancer vaccine developed from identified neoantigens in solid tumors in the form of synthetic long peptides (SLPs) (Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 2611-2611).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03633110||Phase Ib/II||GEN-009 GEN-009 + Nivolumab||Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine||Active, not recruiting|